Charles Schwab Investment Management Inc Corbus Pharmaceuticals Holdings, Inc. Transaction History

Charles Schwab Investment Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.21 - $0.53 $20,877 - $52,690	99,416 New	99,416 $26,000
Q1 2022 May 13, 2022	SELL	$0.32 - $0.67 $14,386 - $30,122	-44,959 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$1.01 - $1.82 $474,762 - $855,512	-470,062 Reduced 91.27%	44,959 $46,000
Q2 2021 Aug 16, 2021	SELL	$1.39 - $2.21 $3,291 - $5,233	-2,368 Reduced 0.46%	515,021 $943,000
Q1 2021 May 17, 2021	BUY	$1.27 - $3.42 $89,362 - $240,644	70,364 Added 15.74%	517,389 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$0.94 - $1.89 $31,669 - $63,675	-33,691 Reduced 7.01%	447,025 $559,000
Q3 2020 Nov 13, 2020	BUY	$1.5 - $9.38 $473,853 - $2.96 Million	315,902 Added 191.67%	480,716 $866,000
Q2 2020 Aug 14, 2020	SELL	$4.79 - $8.39 $17,119 - $29,985	-3,574 Reduced 2.12%	164,814 $1.38 Million
Q1 2020 May 15, 2020	BUY	$3.44 - $7.21 $40,571 - $85,034	11,794 Added 7.53%	168,388 $883,000
Q4 2019 Feb 07, 2020	BUY	$4.29 - $5.64 $82,277 - $108,169	19,179 Added 13.96%	156,594 $856,000
Q2 2019 Aug 09, 2019	BUY	$6.6 - $7.8 $87,859 - $103,833	13,312 Added 10.73%	137,415 $953,000
Q1 2019 May 14, 2019	BUY	$5.76 - $8.95 $90,662 - $140,873	15,740 Added 14.53%	124,103 $863,000
Q4 2018 Feb 14, 2019	SELL	$5.26 - $7.97 $6,364 - $9,643	-1,210 Reduced 1.1%	108,363 $633,000
Q2 2018 Aug 08, 2018	BUY	$5.05 - $6.8 $64,135 - $86,360	12,700 Added 13.11%	109,573 $554,000
Q4 2017 Jan 17, 2018	BUY	$6.6 - $7.78 $148,981 - $175,617	22,573 Added 30.38%	96,873 $688,000
Q3 2017 Nov 13, 2017	BUY	$5.75 - $7.75 $427,225 - $575,825	74,300	74,300 $532,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.